An interventional study of Fact box in COVID-19 and Influenza, sponsored by Harding Center for Risk Literacy. Completed at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Harding Center for Risk Literacy · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 226 studies in COVID-19 with a site in Germany — 21 open to participants now, 27 under way, 7 of them phase 3. COVID-19 · Germany.
Among the 226 studies in COVID-19 with a site in Germany, this one is the 60th largest by enrollment of the 130 interventional ones that give a count, is one of 5 that started in 2023, is one of 35 with no phase, and was the 216th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →21 of the 226 studies in COVID-19 with a site in Germany are open now. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
Pfizer · Sites in Germany, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Germany, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Germany, United States, Argentina and 21 more countries
Ages 18+
Technical University of Munich · Sites in Germany, Austria, Belgium and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
226 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 48 · Phase 3 46 · Phase 4 5
First in 2016; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 135 across the 130 interventional studies, 410 across the 94 observational. Of the 153 that completed or were terminated, 48 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 226 have an industry lead sponsor. The 10 most frequent:
Harding Center for Risk Literacy is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Harding Center for Risk Literacy has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
9 of the studies in COVID-19 with a site in Germany that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03188796Phase 3Medical University of GrazThe VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients | 2027-07 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05389319University Hospital TuebingenA Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 226 studies in COVID-19 with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to evaluate whether evidence-based fact boxes on COVID-19 and influenza vaccination contribute to the decision making of laypeople from different social backgrounds in different educational settings (e.g. medical practices, outreach work). Furthermore, the study will investigate whether evidence-based fact boxes can contribute to more equitable health care by improving shared decision-making.
Background
Evidence-based health information (EBHI) and decision aids (DA) are key components for improving health care by enabling more people to make informed decisions. However, despite their overall effectiveness, there is a risk that only certain groups of the population will benefit from them. Because although they are target group oriented, the factors that lead to inequality in terms of shared and informed decision-making have not yet been sufficiently taken into account in their development process. For example, there are many patient-oriented materials written at an advanced level, which makes the materials less accessible to people with reading difficulties, lower education, health literacy or socioeconomic status (SES).
Evidence-based fact boxes have been shown to support informed decision-making. However, few studies have analysed how the boxes support decision-making in different social groups. Further, it is unclear whether fact boxes promote informed and shared decision making equally when implemented by health educators (HE) in different settings. Hence, there is a risk that fact boxes will only help less disadvantaged people to make informed health decisions.
Objective
In a Multi-center, cluster-randomised, cross-sectional study, the effectiveness of evidence-based fact boxes (intervention) compared with usual health education/care (control) on outcomes relevant to the decision to vaccinate will be investigated in people from different backgrounds in Germany.
Fact boxes on COVID-19 and influenza vaccination have been adapted in several steps to meet the information needs and requirements of the population. This included feedback from various public health stakeholders on a COVID-19 fact box implemented in Germany in January 2021 by a national Public Health institute, the identification of information needs and requirements of the population in Germany based on secondary data analyses, and testing of COVID-19 fact boxes in pre-studies in population-wide surveys with N=1,942 to N=6,056 respondents in Germany. The data basis and individual studies have been described in detail elsewhere.
The Influenza vaccination fact box was updated in 2021 based on current evidence and is available on the Harding Center website for older people (65 years and older) and for people aged 16 to 65. During cognitive interviews, simplified COVID-19 and Influenza vaccination fact boxes were first piloted with German-speaking laypeople and adapted based on their feedback. Visualized COVID-19 fact boxes were also piloted with Arabic-, Turkish- and Russian-speaking laypeople from disadvantaged neighbourhoods in Berlin. A visualized flu fact box is currently being piloted by the University of Erfurt with German-speaking lay people.
Main research question
Do disadvantaged people benefit to the same extent as non-disadvantaged people in terms of informed and shared decision-making from receiving COVID-19 and influenza vaccination fact boxes as opposed to standard vaccination communication in medical practices and outreach work (field settings)?
Research questions (RQ) and main hypotheses (HYP)
RQ1 Is the use of fact boxes more effective than standard vaccine communication (control condition) in the field?
Primary HYP
Secondary HYP
RQ2 Are fact boxes as effective for people with disadvantaging factors as for those without factors associated with disadvantages?
Primary HYP
Compared to standard vaccine communication, fact boxes will lead to a greater alignment of knowledge, informed vaccination intentions, and accuracy of risk perception between:
RQ3 Does the use of fact boxes in outreach work promote more shared and informed decision-making than in regular health care settings?
HYP
a) Compared to standard vaccine communication fact boxes will more likely lead to more informed vaccination intentions and shared decisions in outreach work than in regular health care settings.
Explorative analyses
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Health educators (HE) will receive a flyer with a brief description of the study, a Quick Response-code (QR-code) and a link to an online survey, including either a fact box as tabular format or a visualization on the reverse side about COVID-19 or the flu vaccine to distribute to potential study participants. HE are free to decide if and how to use the fact boxes: whether during, before or after vaccination education, and who to target. Participants who receive the flyer from their HE can decide on their own to participate in the study by using the QR-code or link on the flyer.
Other: Fact box
Study participants whose HE will be randomised to the control will receive the same flyer but without a fact box on the reverse side.
Fact boxes provide a tabular or graphical overview of the benefits and harms of the COVID-19 or influenza vaccination through transparent risk communication. The fact boxes are available for two different age groups each: COVID-19 vaccination for people aged 18 to 59 and over 60, influenza vaccination for people aged 16 to 64 and over 65 in Arabic, German, Russian and Turkish.
Knowledge
10 items: five items on basic knowledge of the disease (e.g. how is Corona or the flu contracted and what are the possible baseline risks) and uncertainty (e.g. quality of evidence), each with 4 possible answers, of which only one is correct. A further five questions that can only be answered through the fact box, including one question on the benefits of vaccination gist and three questions on the benefits and harms of vaccination verbatim. Responses will be graded according to the best available evidence in July 2023.
Time frame: at T1 (initial survey; study period: 3-6 month)
Informed vaccination intention
Based on vaccination knowledge, a person's attitudes and vaccination intentions. Knowledge will be measured as described above. Attitudes will be measured using an 11-point Likert scale that captures the personal assessment of the balance between the potential benefits and risks of the respective vaccine. Vaccination intention will be measured by asking whether participants would have themselves or their relatives vaccinated at the next opportunity, on a scale of 1-5 (Definitely yes, probably yes, probably not, definitely not, I cannot yet say / am still undecided).
Time frame: at T1 (initial survey; study period: 3-6 month)
Risk perception
Based on a frequency format (Please imagine 10 people like yourself: How many of them will be re-infected with COVID-19 after a previous coronavirus infection if they come into contact with a person who is infected with the coronavirus variant XBB.1.5?; How many will contract influenza in a year if the virus is widespread?): Correct responses (reflected the best available evidence, which can be found in the fact boxes together with the medical references.
Time frame: at T1 (initial survey; study period: 3-6 month)
Decisional conflict
The 4-item SURE (Sure of myself; Understand information; Risk-benefit ratio; Encouragement) screening test will be used (if yes: 1, if no: 0; a score of \< 4 is a positive result for decisional conflict)
Time frame: at T1 (initial survey; study period: 3-6 month)
Patient involvement in decision making
Measured with the 9-item Shared Decision Making Questionnaire (SDM-Q-9). The instrument contains nine statements which are rated on a six-point Likert scale (from 0 'completely disagree' to 5 'completely agree').
Time frame: at T1 (initial survey; study period: 3-6 month)
Health literacy
Measured by using the established and validated 12-item Health Literacy Survey Questionnaire (HLS19-Q12), a short form questionnaire of the 47-item Health Literacy Survey Questionnaire (HLS19-Q47) for measuring comprehensive, general health literacy (HL) in general adult populations. After an introductory statement about handling health information, respondents are asked to choose one of four response categories to the 12 questions about how easy or difficult tasks related to handling health information are (with 4 'very easy', 3 'easy', 2 'difficult', 1 'very difficult').
Time frame: at T1 (initial survey; study period: 3-6 month)
Subjective socioeconomic status
Will be assessed by using the MacArthur Scale of Subjective Social status (SSS), which measures the subjective perception of social position within society on a 10-point scale (with SSS low: 1-4, middle: 5-6, high: 7-10).
Time frame: at T1 (initial survey; study period: 3-6 month)
Plan to share: Yes — All relevant data will be provided in the manuscript and supporting information or made available in a public repository after completion of the study.
Time frame: After completion of the study.
Access criteria: All relevant data will be provided in the manuscript and supporting information or made available in a public repository (e.g., OSF) after completion of the study.
Ran from Nov 2023 to primary completion in Mar 2025, 16 months.
Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 16 months is above that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Nov 2024 → Mar 2025 and completion Dec 2024 → May 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Harding Center for Risk Literacy